Objective: To determine in patients with systemic lupus erythematosus (SLE) or with primary antiphospholipid syndrome (PAPS) the prevalence of cerebral magnetic resonance imaging changes (MRI) and the relationship with antiphospholipid antibodies.
Methods: Twenty-nine consecutive SLE patients, 24 PAPS patients and 31 healthy controls were prospectively included in the study and underwent MRI Scan over a 1-year period. MRI scans were analyzed separately by a neuroradiologist for white matter changes [periventricular hyperintensity (PVH) (0–6 scale), deep white matter hyperintensity (WMH) (0–24 scale)], and one neurologist for cerebral atrophy (0–39 scale) and stroke subtypes. Statistical assessment consisted of a discriminant analysis performed with SAS-package with MRI data as dependent variables and, as independent variables, age, sex, arterial hypertension, diabetes mellitus, cardiopathy, migraine, neurological symptoms, antiphospholipid antibodies, SLE, steroid treatment.
Results: The prevalence of cerebral atrophy was increased in both SLE and PAPS groups relative to controls. PVH and WMH scores were significantly higher in SLE and PAPS than in controls. Focal infarct did not differ in the SLE group when compared with PAPS. PVH and WMH scores were significantly higher in patients with neurological symptoms. Using a correlation test we found a weak significant correlation between cerebral atrophy and lupus anticoagulant. The multivariate analysis found only three independent variables related to PVH and WMH: age, the diagnosis of SLE and cerebral atrophy.
Conclusions: Age, presence of SLE and presence of neurological symptoms were independently related with WMH and PVH, but not antiphospholipid antibodies.
Asherson RA et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome . Am J Med1989; 86: 391–399 .
2.
Briley DP , Coull BM , Goodnight SH . Neurological disease associated with antiphospholipid antibodies . Ann Neurol1989; 25: 221–227 .
3.
Levine SR , Deegan MJ , Futrell N , Welch KMA . Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases . Neurology1990; 40: 1181–1189 .
4.
West SG , Emlen W , Wener MH , Kotzin BL . Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests . Am J Med1995; 99: 153–163 .
5.
Hachulla E , Leys D , Deleume JF , Pruvo JP , Devulder B . Manifestations neurologiques associées aux anticorps antiphospholipides. Ou que reste-t-il du neurolupus?Rev Méd Interne1995; 16: 121–130 .
6.
Harris EH et al. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies . Clin Exp Rheumatol1984; 2: 47–51 .
7.
Harris EN et al. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies . Ann Rheum Dis1985; 44: 281–283 .
8.
Asherson RA . A ‘primary’ antiphospholipid syndrome?J Rheumatol1988; 15: 1742–1746 .
9.
The Antiphospholipid Antibodies in Stroke Study (APASS) Group . Anticardiolipin antibodies are an independent risk factor for first ischemic stroke . Neurology1993; 43: 2069–2073 .
10.
Fields RA , Toubbeh H , Searles RP . The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies . J Rheumatol1989; 16: 623–625 .
Awad IA et al. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I: correlation with age and cerebrovascular risk factors . Stroke1986; 17: 1084–1089 .
13.
Gerard G , Weisherg LA . MRI periventricular lesions in adults . Neurology1986; 36: 998–1001 .
14.
Sarpel G , Chaudry F , Hindo W . Magnetic resonance imaging periventricular hyperintensity in a Veterans Administration hospital population . Arch Neurol1987; 44: 725–728 .
15.
Fazekas F . Magnetic resonance signal abnormalities in asymptomatic individuals; their incidence and functional correlates . Eur Neurol1989; 20: 164–168 .
16.
Leys D et al. Periventricular and white matter magnetic resonance imaging hyperintensities do not differ between Alzheimer's disease and normal aging . Arch Neurol1990; 47: 524–527 .
17.
Scheltens P et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging . J Neurol Sci1993; 114: 7–12 .
18.
Schmidt R et al. Anticardiolipin antibodies in normal subjects neuropsychological correlates and MRI findings . Stroke1995; 26: 749–754 .
19.
Ravelli A , Caporali R , Montecucco C , Martini A . The antiphospholipid syndrome in childhood . J Rheumatol1996; 23: 1121–1122 .
20.
Bell CL et al. Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers . Arthritis Rheum1991; 34: 432–441 .
21.
Jarek MJ , West SG , Baker MR , Rak KM . Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus . Arthritis Rheum1994; 37: 1609–1613 .
22.
Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271–1277 .
23.
Asherson RA et al. The primary anphospholipid syndrome: major clinical and serological features . Medicine (Baltimore)1989; 68: 366–374 .
Harris EN , Gharavi AE , Patel SP , Hughes GVR . Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986 . Clin Exp Immunol1987; 68: 215–222 .
27.
Brandt JT , Triplett DA , Alving B , Scharrer I . Criteria for the diagnosis of lupus anticoagulants: an update . Thromb Haemost1995; 74: 1185–1190 .
28.
Triplett DA , Brandt JT , Kaczor D , Schaeffer J . Laboratory diagnosis of lupus inhibitors: a comparison of tissue thromboplastin inhibition procedure with a new platelet neutralization procedure . Am J Clin Pathol1983; 79: 678–682 .
29.
Arvieux J et al. Species specificity of anti-b2-glycoprotein I autoantibody and its relevance to anticardiolipin antibody quantitation . Thromb Haemost1996; 75: 725–730 .
30.
Pasquier F et al. Inter-and intra-observer reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts . Eur Neurol1996; 36: 268–272 .
31.
SAS Institute Inc.SAS User's Guide. Statistics: Version6 EditionCary, NC: SAS Institute Inc , 1990.
32.
Herranz MT et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus . Arthritis Rheum1994; 37: 568–571 .
33.
Sammaritano LR , Gharavi AE , Lockshin MD . Antiphospholipid antibody syndrome: immunologic and clinical aspects . Sem Arthritis Rheum1990; 20: 81–96 .
34.
Silvetrini M et al. Migraine in patients with stroke and antiphospholipid antibodies . Headache1993; 33: 421–426 .
35.
Ginsburg KS et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis . Ann Intern Med1992; 117: 997–1002 .
36.
Fazekas F et al. Comparison of CT, MR, and PET in Alzheimer's dementia and normal aging . J Nucl Med1989; 30: 1607–1615 .
37.
Schmidt R et al. Magnetic resonance imaging white matter lesions and cognitive impairment in hypertensive individuals . Arch Neurol1991; 48: 417–420 .
38.
Fazekas F . Magnetic resonance signal abnormalities in asymptomatic individuals; their incidence and functional correlates . Eur Neurol1989; 29: 164–168 .
39.
Zimmerman RD et al. Periventricular hyperintensities as seen my magnetic resonance prevalence and significance . Am J Neuroradiol1986; 146: 443–450 .
40.
Aisen AM , Gabrielson TO , McCune WJ . MR imaging of systemic lupus erythematosus involving the brain . Am J Neuroradiol1985; 6: 197–201 .
41.
Jacobs L et al. Central nervous system lupus erythematosus the value of magnetic resonance imaging . J Rheumatol1988; 16: 601–606 .
42.
McCune WJ , MacGuire A , Aisen A , Gebarski S . Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning . Arthritis Rheum1988; 31: 159–166 .
43.
Sewell KL , Livneh A , Aranow CB , Grayzel AI . Magnetic resonance imaging versus computed tomographic scanning in neuropsychiatric systemic lupus erythematosus . Am J Med1989; 86: 625–626 .
44.
Sibbitt WL et al. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus . Ann Rheum Dis1989; 48: 1014–1022 .
45.
Bell CL et al. Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus: correlation with clinical remission and antineurofilament and anticardiolipin antibody titers . Arthritis Rheum1991; 34: 432–441 .
46.
Kinnunen E , Järvinen P , Ketonen L , Sepponen R . Co-twin control study on cerebral manifestations of systemic lupus erythematosus . Acta Neurol Scand1993; 88: 422–426 .
47.
Ishikawa O , Ohnishi K , Miyachi Y , Ishizaka H . Cerebral lesions in systemic lupus erythematosus detected by Magnetic Resonance Imaging . J Rheumatol1994; 21: 87–90 .
48.
Stimmler MM , Coletti PM , Quismorio FP . Magnetic Resonance Imaging of the brain in neuropsychiatric systemic lupus erythematosus . Sem Arthritis Rheum1993; 22: 335–349 .
49.
Kaye R , Neuwelt C , London S , De Armond J . Central nervous system systemic lupus erythematosus mimicking progressive multifocal leucoencephalopathy . Ann Rheum Dis1992; 51: 1152–1156 .
50.
Chinn RJS et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus . Arthritis Rheum1997; 40: 36–46 .
51.
Molad Y et al. Lupus anticoagulant: correlation with Magnetic Resonance Imaging of brain lesions . J Rheumatol1992; 19: 556–561 .
52.
Kinnunen E et al. MS and SLE in twins of successive generations . Acta Neurol Scand1990; 81: 246–249 .
53.
Bentson J , Reza M , Winter J , Wilson G . Steroids and apparent cerebral atrophy on computed tomography scans . J Comput Assist Tomogr1978; 2: 16–23 .
